Study of ependymoma treatment resistance in children
Part of Brain & nervous system, Cancer clinical trials.
This trial looks at why ependymoma can resist (be harder to treat) after radiation or treatment. It studies children who are already being followed in specific existing programs, which may help researchers find better treatment approaches in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a child or adolescent with an intracranial ependymoma (a brain/spinal cord tumor of ependymal cells)
- You have already received treatment for your ependymoma
- You are enrolled in one of these specific studies/programs: PEPPI, pediaRT, or the SIOP II Ependymoma French program
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests different follow-up treatments for children with brain ependymoma after their initial surgery. Which treatment you get depends on how much tumor is left (if any) and whether the child can safely receive radiation and chemotherapy.
This early-phase study tests a more precisely targeted type of radiation for children with ependymoma, aiming to treat the brain tumor more accurately. It may help reduce how much healthy tissue gets radiation, and researchers are checking safety and best dosing.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial studies how brain tumors (like high-risk gliomas, medulloblastoma, and ependymoma) respond to treatment and why they sometimes become resistant. It is for young people aged 15 to 39 and aims to use tumor tissue samples to understand the tumor better and guide future therapies.
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
Hear when a new Pediatric Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.